MedTrace Logo

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

NCT01598025 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2018-08-09

Study results available
· View outcomes & findings →

Summary

Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors.

This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.

Conditions

Interventions

RADIATION

total-body irradiation (TBI)

DRUG

thiotepa

DRUG

fludarabine phosphate

DRUG

melphalan

BIOLOGICAL

anti-thymocyte globulin

PROCEDURE

allogeneic hematopoietic stem cell transplantation

BIOLOGICAL

peripheral blood stem cell transplantation

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

Principal Investigators

  • Richard O'Reilly, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-02
Primary Completion
2017-10-16
Completion
2017-10-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01598025 on ClinicalTrials.gov